Skip to content
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc.

RXRX

Recursion is a clinical-stage TechBio company that integrates artificial intelligence, machine learning, and automated wet-lab biology to industrialize drug discovery.

Market cap
$1.6B-36.6%
Revenue$66.4M+11.1%
Net income-$559.8M+2.6%
Free cash flow-$325.8M+18.1%
EPS (diluted)-$1.16+35.9%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$11.0M
EPS estimate-$0.25

Financials

Q1 2026

Income statement

See full
Revenue$6.5M-56.1%
Gross profit-$6.0M+15.0%
Operating income-$128.5M+32.8%
Net income-$117.5M+42.0%
EPS (diluted)-$0.22+56.0%

Balance sheet

See full
Cash & equivalents$665.2M+30.6%
Total debt$88.6M-24.6%
Total equity$1.0B+9.7%
Total assets$1.3B+2.6%

Cash flow

See full
Operating cash flow-$81.1M+38.5%
CapEx$258.0K-85.9%
Free cash flow-$81.4M+39.2%

Valuation & ratios

Valuation

See full
Market cap$1.6B-36.6%
Enterprise value$1.02B-55.9%
P/S24.1×-18.3×

Profitability

See full
Gross margin7.2%
Operating margin-881.3%-66.8pp
Net margin-842.9%-92.4pp
FCF margin-490.7%-102pp

Returns & leverage

See full
Return on equity-57.2%-14.4pp
Debt / equity0.1×0.0×
Current ratio5.5×+1.4×

Segments

By product

See full
Operating revenue$6.3M-57.5%
Grant revenue$171.0K+334%

By segment

See full
Reportable Segment$6.5M-56.1%

Competitors

Profile

Recursion is a clinical-stage TechBio company that integrates artificial intelligence, machine learning, and automated wet-lab biology to industrialize drug discovery. The company utilizes its proprietary Recursion Operating System (OS) to decode biological patterns and identify novel treatments across various therapeutic areas. By shifting from a traditional high-attrition discovery funnel to an AI-native 'T-shaped' model, the company aims to increase the probability of clinical success while reducing the time and cost of drug development.

Competitive position

A leading TechBio pioneer focused on replacing traditional trial-and-error drug discovery with a scalable, AI-driven automated platform.

GeographiesUnited States
Customer segmentsBiopharmaceutical companies, Clinical trial participants
Business modelR&D-based drug development, Strategic licensing and collaboration
SuppliersCloud computing infrastructure, Laboratory equipment suppliers, Biological data sources, Chemical library providers
CustomersLarge pharmaceutical companies, Hospitals and health systems, Specialty pharmacies
Listed2021
Employees500.0
CEONajat Khan
FilingsSEC EDGAR

Questions, answered.

What is Recursion Pharmaceuticals, Inc.'s market cap?
Recursion Pharmaceuticals, Inc. (RXRX) has a market capitalization of $1.6B and trades on NASDAQ.
What is Recursion Pharmaceuticals, Inc.'s revenue and profitability?
Recursion Pharmaceuticals, Inc. generated $66.4M in trailing twelve-month revenue with a net loss of $559.8M, representing a net margin of -842.9%. Gross margin stands at 7.2%, with free cash flow of -$325.8M. These figures are based on the Q1 2026 filing.
Who are Recursion Pharmaceuticals, Inc.'s competitors?
Recursion Pharmaceuticals, Inc.'s key competitors include AbCellera, Schrodinger, Relay Therapeutics, and others. These companies compete in similar markets and product categories.
Who does Recursion Pharmaceuticals, Inc. partner with?
Recursion Pharmaceuticals, Inc.'s notable partners include NVIDIA, Roche, Bayer.
What subsidiaries does Recursion Pharmaceuticals, Inc. have?
Recursion Pharmaceuticals, Inc.'s subsidiaries include Valence Labs.
Where is Recursion Pharmaceuticals, Inc. headquartered?
Recursion Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 500 people. It has been publicly traded since 2021.